Abstract
The study is relevant due to an increase of oncological diseases and its complications from tumor growth or treatment. Research purpose : to study in an experiment the formation of pathomorphological changes in kidney tissue, taking into account the development of the tumor process and cytostatic therapy. Research objectives : to study morphological changes in the kidneys caused by the tumor process in an animal experiment; to study the effect of methotrexate on the dynamics of pathomorphological changes in the kidneys; to identify of the severity of pathomorphological changes in experimental groups. Materials and methods . We conduct the study on Balb/c mice according to the recommendations set out by the Ministry of Health of the USSR no. 755 and the Helsinki Declaration. Euthanasia was performed by administration of sodium thiopental. The control group was represented by mice without formed tumors. Experimental groups were formed from animals with tumors. Pathomorphological changes in the kidneys were studied both without the administration of methotrexate and with the use of methotrexate. Cytostatic was administered in a dosage of 0.2 mg. Pathomorphological studies of tumors and kidneys were carried out according to the standard histological technique. Results . In experimental groups of animals with a tumor process, nonspecific pathomorphological changes prevailed in the form of irreversible necrobiotic and microcirculatory changes in both cortical and cerebral sections of nephrons, while fibroplastic and microcirculatory changes prevailed when methotrexate was administered. Conclusion . The severity of pathomorphological changes in the kidneys depended on the presence of a tumor process and the effects of methotrexate.
Publisher
Tambov State University - G.R. Derzhavin
Reference18 articles.
1. Dzhadranov E.S., Ibadullaeva G.S., Boshkaeva A.K., Ergazina M.Zh., Krasnoshtanov A.V., Krasnoshta-
2. nov V.K., Bekebaev N.K. Structural features of spontaneous mammary tumors of laboratory mice and rats. Vestnik KazNMU. 2017;(1):399-401. (In Russian).
3. Suvorin P.A., Khoronenko V.E., Zharkov P.A., Baskakov D.S. Prevention of venous thromboembolism in cancer patients. P.A. Herzen Journal of Oncology. 2017;6(1):71-5. (In Russian). DOI 10.17116/onkolog20176171-75
4. Ptushkin V.V. Current approaches to treating thrombotic events in oncology. P.A. Herzen Journal of Oncology. 2017;6(5):103-6. (In Russian). DOI 10.17116/onkolog201765103-106
5. Ter-Ovanesov M.D., Madzhuga A.V. Thrombotic complications in oncology: experience implemented in practice. Practical Oncology. 2001;(5):25-32. (In Russian).